Skip to main content
I

iotaSciences

The startup has developed a fluid-shaping technology that replaces traditional microtiter plates with a microscale system for single-cell cloning, allowing researchers to expose cells to relevant experimental conditions. This technology enables multiple users to conduct simultaneous experiments efficiently, addressing the limitations of current cloning methods.

Oxford, United KingdomFounded 2016171K+ followers
Updated 3 months ago

Funding

$11.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Traditional single-cell cloning methods, such as limiting dilution, are inefficient, wasteful, and lack reliable confirmation of monoclonality, requiring large amounts of expensive reagents and manual effort. These methods also struggle to maintain high cell viability during isolation and handling.

Solution

Iota Sciences provides automated solutions for gentle single-cell isolation and cloning, enabling researchers to increase the speed and efficiency of cell biology research. Their technology utilizes low-volume cell culture chambers (GRIDs) to dispense and culture single cells efficiently in nanoliter volumes, reducing reagent consumption and providing exceptional optical clarity for monoclonality verification. The modular systems automate tedious pipetting steps, maintain optimal cell viability, and offer flexible transfer of single cells into various formats compatible with downstream assays. Iota Sciences' platforms streamline workflows for applications such as CRISPR-Cas9 gene editing, single-cell omics, and cell line development, helping researchers generate more clones with less effort and cost.

Target Audience

Iota Sciences' primary customers are researchers in cell biology, including those working in CRISPR-Cas9 gene editing, single-cell omics, and cell line development, as well as institutes and companies involved in iPSC and recombinant protein production.

Features

  • Automated single-cell cloning and isolation platforms
  • Low-volume cell culture chambers (GRIDs) for efficient single-cell culture in nanoliter volumes
  • Gentle cell handling for optimal viability
  • Whole-chamber imaging for reliable monoclonality assessment
  • Automated plating, feeding, and harvesting
  • Flexible transfer of single cells into various formats (96-well plates, PCR tubes, mass-spec vials)
  • Intuitive touchscreen interface
  • Compatibility with a wide range of reagents
This profile is AI-generated and may contain inaccuracies.